Aggregate distributional cost-effectiveness analysis of biologics for the treatment of ankylosing spondylitis in Chile

Walbaum, Magdalena ORCID: 0000-0002-2179-9224 and Jana-Valencia, Nicolas (2025) Aggregate distributional cost-effectiveness analysis of biologics for the treatment of ankylosing spondylitis in Chile. Applied Health Economics and Health Policy. ISSN 1175-5652 (In Press)

Text (Equity impact of biologics for ankylosing spondylitis in Chile Walbaum) - Accepted Version Pending embargo until 1 January 2100. Available under License Creative Commons Attribution. Download (481kB)

Abstract

Background Ankylosing spondylitis is a complex rheumatic disease, characterised by chronic and progressive inflammation of the spine, causing important health and economic burden for the person with the condition. Evidence shows the unequal impact of the disease in different groups of people, with higher burden for lower socioeconomic groups. The objective of this study is to evaluate the impact of the use of biologics for the treatment of ankylosing spondylitis on health inequities in Chile. Methods We conducted an aggregate distributional cost-effectiveness analysis. Data on health outcomes and costs were derived from a cost-effectiveness model of Secukinumab, Etanercept, Certolizumab Pegol, Infliximab, Adalimumab, and Golimumab versus treatment as usual for the treatment of ankylosing spondylitis from the Chilean healthcare system perspective. Health gains and health opportunity costs were distributed across socio-economic subgroups. Health and equity impacts, measured using the Atkinson index, were assessed on an equity-efficiency impact plane. Results All treatments had a positive impact on equity relative to treatment as usual. At opportunity cost threshold of 1 GDP per capita/quality-adjusted life year (QALY), Secukinumab improved societal welfare irrespective of the Atkinson index value. When varying thresholds (2 and 3 GDP), all assessed technologies contributed to an increase in societal welfare, regardless of the Atkinson index. Conclusions Biologic treatment for ankylosing spondylitis, such as Secukinumab, may reduce health inequity in the Chilean population. Aggregate distributional cost-effectiveness analysis framework is feasible to implement alongside cost-effectiveness analyses in the context of Chile healthcare system to provide additional information of equity impacts for health technology assessment recommendations and policy making.

Item Type:	Article
Additional Information:	© 2025 The Author(s)
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine H Social Sciences > HB Economic Theory R Medicine
Date Deposited:	01 May 2025 15:36
Last Modified:	01 May 2025 15:42
URI:	http://eprints.lse.ac.uk/id/eprint/128046

Actions (login required)

View Item